Summary of safety over the 6-month treatment period*
| Abatacept (n = 28) | Placebo (n = 28) | |
|---|---|---|
| AEs, n (%) | 18 (64.3) | 20 (71.4) |
| Discontinuations due to AEs | 1 (3.6) | 1 (3.6) |
| Serious AEs, n (%) | 1 (3.6) | 1 (3.6) |
| Discontinuations due serious AEs | 0 | 0 |
| Infections, n (%) | 10 (35.7) | 11 (39.3) |
| Malignancies, n (%) | 1 (3.6) | 0 |
| Deaths, n (%) | 0 | 0 |
↵* Including a follow-up period of up to 56 days after the last dose of study drug.
AE, adverse event.